Actively Recruiting
Nab-P+Cb+PD1 Inhibitors as Neoadjuvant Therapy for Early TNBC
Led by Henan Cancer Hospital · Updated on 2025-12-05
64
Participants Needed
1
Research Sites
81 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
We plan to explore the efficacy and safety of albumin-bound paclitaxel+carboplatin+Camrelizumab in neoadjuvant therapy for early TNBC patients, optimize the administration method and drug combination therapy.
CONDITIONS
Official Title
Nab-P+Cb+PD1 Inhibitors as Neoadjuvant Therapy for Early TNBC
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Female aged 18 to 65 years
- Diagnosed with clinical T2 to T4d or T1c breast cancer with axillary lymph node metastasis
- Confirmed triple-negative invasive breast cancer by histopathology (ER and PR negative, HER-2 negative)
- Measurable lesions by ultrasound, mammography, or optional MRI within 1 month before screening
- Adequate organ and bone marrow function within 2 weeks before chemotherapy
- Cardiac ultrasound ejection fraction at least 55%
- Negative pregnancy test for women of childbearing age within 14 days before randomization
- ECOG performance status of 0 or 1
- Able and willing to provide informed consent
You will not qualify if you...
- Evidence of metastatic breast cancer confirmed by imaging before diagnosis and randomization
- Prior chemotherapy, endocrine therapy, targeted therapy, or radiation for this breast cancer
- Second primary malignant tumor except fully treated skin cancer
- Previous treatment with anti-PD-1, anti-PDL1, anti-PD-L2, or other immunotherapy
- Diagnosed with immunodeficiency or autoimmune diseases
- Severe lung or heart disease
- Active hepatitis B or C infection
- History of organ or bone marrow transplantation
- Pregnant or breastfeeding women
- Serious medical conditions contraindicating chemotherapy
- Significant bleeding symptoms or bleeding tendency in the previous month
- Arteriovenous thrombosis events like deep vein thrombosis or pulmonary embolism within the previous 3 months
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Henan cancer hospital
Zhengzhou, Henan, China
Actively Recruiting
Research Team
Z
Zhenzhen Liu
CONTACT
Y
Yajie Zhao
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here